BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Neutral 47.9%

Neg 0% Neu 47.9% Pos 0%

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $50 to $40.